Adjusting overall survival for treatment switch
|
|
- Cori Charles
- 6 years ago
- Views:
Transcription
1 Adjusting overall survival for treatment switch Recommendations of a crossinstitutional statistical working group Claire Watkins Director and Consultant Statistician, Clarostat Consulting Ltd Cytel East User Group Meeting London, 16 th March 2016
2 Outline The working group Background Methods simple/naïve, complex Example Method selection process Best practice design and analysis 2
3 Treatment switch subteam of the PSI HTA SIG Remit and membership (past and present) Amongst pharmaceu0cal industry sta0s0cians working with trials including treatment switches: Raise awareness Current sta*s*cal methods Poten*al applica*ons Strengths and limita*ons Promote and share best prac0ce, in both analysis and design Encourage research into new and improved methods [Chair] Claire Watkins (Clarostat Consulting) Pierre Ducournau (Roche) Rachel Hodge (GSK) Xin Huang (Pfizer) Cedric Revil (Roche) 3 Alexandros Sagkriotis (Novartis) Yiyun Tang (Pfizer) Jason Wang (Celgene) Elaine Wright (Roche) [Non-member advisory role] Nicholas Latimer (University of Sheffield)
4 Key publications 4
5 Background What do we mean by treatment switch/crossover? Patients in a parallel group RCT may switch or crossover to the alternative treatment at some point before an endpoint of interest occurs. We might build this into the trial protocol e.g. Sunitinib GIST trial (Demetri, 2012) Or it might happen spontaneously due to clinical practice in the region, if the treatment is already on the market e.g. Gefitinib IPASS trial (Fukuoka, 2011) Randomise Randomise Sunitinib Placebo Gefitinib Doublet chemo Disease prog Disease prog Sunitinib Standard clinical practice (inc gef) Survival Survival 5
6 Potential impact of treatment switch Correlation between PFS and OS in NSCLC Switch prohibited (n=20) R 2 = Switch allowed (n=15) R 2 = Interaction p=0.019 Hotta et al: Progression-free survival and overall survival in phase III trials of moleculartargeted agents in advanced non-small-cell lung cancer. Lung Cancer 79 (2013)
7 Switching Regulatory vs HTA viewpoint Regulatory agency Evaluate efficacy in clinical trial Switch happened in clinical trial Do not adjust OS to remove switch - ITT primary May consider switch adjusted OS as a supportive analysis Primary endpoint may not be OS anyway Health Technology Assessment (HTA) Agency Evaluate effectiveness in real world setting Switch real world (mostly) Use plausible methods* to adjust OS to remove switch If no plausible methods, use ITT Key endpoint for lifetime cost effectiveness calculations is OS * Views of plausible methods differ by agency! 7
8 Why does switching matter for HTA? It all depends on the decision problem In HTA, the decision problem is often to compare: Current clinical practice without new therapy vs Potential future clinical practice including new therapy If there is switching and the new therapy is effective, ITT underestimates this difference How to estimate long term efficacy without switch? 8
9 Commonly used methods to estimate control arm survival in absence of switch Naive methods 1. Exclude switchers 2. Censor at switch 3. Time varying covariate Simple to apply High levels of bias Complex methods 1. Inverse Probability of Censoring Weighting (IPCW; observational) 2. Rank Preserving Structural Failure Time (RPSFT; randomisation based) 3. Iterative Parameter Estimation (IPE; randomisation based) 4. Two-stage Accelerated Failure Time (AFT) Harder to apply Try to reduce bias External data 9
10 Naive (1): Exclude switchers Control arm survival Compare to observed experimental arm survival Observed (ITT) control arm Exclude switchers Non switchers Non switchers Switchers S S Switchers S S Key Death time Censor time S Switch time 10 Assumption: Switchers and nonswitchers have the same prognosis (i.e. no confounders)
11 Naive (2): Censor switchers Control arm survival Compare to observed experimental arm survival Observed (ITT) control arm Censor switchers Non switchers Non switchers Switchers S S Switchers Key Death time Censor time S Switch time 11 Assumption: Switchers and nonswitchers have the same prognosis (i.e. no confounders)
12 Naive (3): Time varying covariate Non-switchers Switchers Confounding Covariate Covariate Switch Death Death 12 Assumption: Switchers and nonswitchers (with the same covariates) have the same prognosis (i.e. no confounders)
13 Complex (1): IPCW (weight non-switched times) Control arm survival Compare to observed experimental arm survival Observed (ITT) control arm IPC weighted Non switchers Non switchers WEIGHT WEIGHT S WEIGHT Switchers S Switchers WEIGHT Key Death time Censor time S Switch time 13 Assumption: The variables in the weight calculation fully capture all reasons for switching that are also linked to survival (i.e. no unmeasured confounders) Weights represent how switch-like a patient is that has not yet switched
14 Statistical detail: IPCW An observational data-based two stage modelling approach Modelling stage 1: Population Control arm patients Model Output Modelling stage 2: Population All patients Model Output Probability of switch over time conditional on baseline and time varying factors (propensity score) Time varying subject specific IPC weights Survival analysis with IPC weights applied to control arm patients (censor at switch) IPC weighted Hazard Ratio and KM 14
15 Complex (2): RPSFT (adjust post switch times) Control arm survival Compare to observed experimental arm survival Observed (ITT) control arm RPSFT adjusted Non switchers Non switchers Switchers S S Switchers Key 15 Time off experimental Death time Censor time S Switch time Time on experimental Time off experimental Treatment Time on multiplier x experimental Assumptions: Each cycle of treatment extends survival by a constant amount. Balanced arms due to randomisation
16 Statistical detail: RPSFTM (Robins 1991) Accelerated Failure Time model structure Works by estimating the treatment effect that balances counterfactual survival time in the absence of treatment [T(0)] between randomised arms T(0) = T off + e ψ T on Survival time without experimental Time off experimental Treatment effect Time on experimental Treatment effect <1 is beneficial (time to death is slowed down on trt) Core assumption: Trt effect is the same regardless of when treated 16
17 Statistical detail: RPSFTM Need to define two states: On and Off treatment Treatment effect estimated using G-estimation (non-parametric) P-value is similar to ITT analysis! What does the constant treatment effect assumption mean? An example Take two identical patients, Bob and Steve On best supportive care (control) only, their survival would be 6m and they would progress at 4m Give them both 1 cycle of experimental treatment Bob has his treatment at the start Steve has his treatment at 4m after progression Constant treatment effect => Bob and Steve still have identical survival (e.g. 7m each) even though treated at different times
18 Complex (3): IPE (adjust post switch times) Essentially the same as RPSFTM Key difference: - Treatment effect is estimated using a parametric model (e.g. Weibull) instead of non-parametric G-estimation - Additional distributional assumption required - May reduce model fitting difficulties of RPSFTM In practice, RPSFTM and IPE results usually very similar
19 Complex (4): 2-Stage AFT (observational study) Control arm survival Compare to observed experimental arm survival Observed (ITT) control arm 2-stage AFT adjusted Non switchers Switchers 19 P P P P S Key Death time Censor time SSwitch time PProgression time S Not valid if switch can occur before progression Treat control arm as observational study post progression Re-baseline at progression Collect covariate data at progression Calculate effect of switch treatment adjusting for covariates Adjust switcher data and compare randomised arms Assumptions: The covariates fully capture all reasons for switching that are also linked to survival No time-dependent confounding between P and S (i.e. no unmeasured confounders)
20 Case study: Sunitinib vs Placebo, GIST Overall Survival (Final, 2008) Overall Survival Probability (%) Total deaths Sunitinib (N=243) Median 72.7 weeks 95% CI (61.3, 83.0) Placebo (N=118) Median 64.9 weeks 95% CI (45.7, 96.0) Hazard Ratio= % CI (0.679, 1.129) p= (87.3%) patients switched from placebo to sunitinib treatment Time (Week)
21 Naïve Analyses ITT (naïve) Cox Model Hazard Ratio (SU/PB), 95% CI and p-value (0.679, 1.129), p=0.306 Dropping switchers (0.178, 0.555), p< Censoring at switch (0.454, 1.499), p=0.527 Time-dependent treatment covariate (0.520, 1.679), p=0.820
22 Overall Survival (Final, 2008) Crossover Adjusted by RPSFT Overall Survival Probability (%) Sunitinib (N=207) Placebo (N=105) Sunitinib (N=243) Median 72.7 weeks 95% CI (61.3, 83.0) Placebo (N=118) Median* 39.0weeks 95% CI (28.0, 54.1) Hazard Ratio= % CI** (0.262, 1.134) p= Time (Week) *Estimated by RPSFT model ** Empirical 95% CI obtained using bootstrap samples.
23 Use of external data Control arm without exposure to experimental RCT RWE Retrospective historical Prospective contemporaneous Ideally Use as external validation of analyses, or quasi-control Comparability to pivotal RCT control arm is key - Patient characteristics, eligibility criteria, treatment, time, location, clinical practice, outcome 23
24 Method selection process Specific process proposed in NICE DSU Technical Support Document 16 (Latimer and Abrams) Key steps (in general): 1. Can the model be fitted with available data? 2. If yes, is the model appropriate given the switching mechanism? 3. If yes, are the assumptions reasonable? 4. If yes, are the results plausible?
25 Summary of data collection requirements for complex methods Data RPSFTM /IPE 2-stage IPCW Date of starting switch treatment!!! Date of death/censoring!!! Date of stopping switch treatment!* All baseline covariates that may!! influence switch decision or OS All time varying covariates that may! influence switch decision or OS, collected until switch or death/censoring All time varying covariates that may! influence switch decision or OS, collected until secondary baseline Date of secondary baseline (usually disease progression)!! * for on-treatment approach only 25 Increasing data collection burden
26 Summary of key assumptions for switch adjustment methods Method ITT Exclude switchers Censor switchers Time varying covariate IPCW RPSFTM IPE 2-stage Key assumptions Switch treatment ineffective No confounders (unlikely) No confounders (unlikely) No confounders (unlikely) No unmeasured confounders Constant treatment effect Balance due to randomisation Constant treatment effect Balance due to randomisation Parametric distribution No unmeasured confounders (stronger assumption than IPCW as fewer covariates in model) 26 If you spend long enough on an island of one-eyed trolls, you will eventually be able to decide which is the most beautiful
27 Best practice recommendations - Trial design Up front planning at design stage Be clear about the question, rationale, customer Describe intent to do analyses in protocol Define switch treatment (drug(s), dose(s) etc) Consider external data sources Collect the data to enable robust analysis 27
28 Best practice recommendations - Analysis Pre-specify preferred adjustment method in protocol/ analysis plan with justification Follow a transparent model selection process Don t use naive as sole or primary method Don t use IPCW/2-stage AFT if most patients switch or near perfect predictor of switch Don t use RPSFTM if near equal exposure or survival Always present ITT Provide results from a range of sensitivity analyses 28 External data assess and take steps to maximise comparability
29 Summary and looking to the future No method is universally best Situation specific assessment required Best practice recommendations have been outlined Be clear on the decision problem Collect the right data Up front planning Further work and research is needed: 29 Multiple switches Multiple switch treatments Different or less strong assumptions Binary or continuous data Software
30 30 Q & A
31 References (1) Watkins C et al. Adjusting overall survival for treatment switches: Commonly used methods and practical application. Pharm Stats 2013 Nov-Dec;12(6): Latimer NR and Abrams KR. NICE DSU Technical Support Document 16: Adjusting survival time estimates in the presence of treatment switching. (2014). Available from Demetri GD et al. Complete longitudinal analyses of the randomized, placebo-controlled, Phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012; 18: Fukuoka M et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29(21): Hotta et al. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer 2013; 79:20-26 Robins J and Finkelstein D. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log-Rank Tests. Biometrics 2000; 56(3): D Agostino RB et al. Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study. Stat Med 1990; 9: Fewell Z et al. Controlling for a time-dependent confounding using marginal structural models. The Stata Journal 2004; 4(4): Hernan MA et al. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men. Epidemiology 2000; 11(5):
32 References (2) Robins JM and Tsiatis A. Correcting for non-compliers in randomised trials using rank-preserving structural failure time models. Communications in Statistics - Theory and Methods 1991; 20: White IR et al. strbee: Randomization-based efficacy estimator. The Stata Journal 2002; 2(2): Huang X and Xu Q. Adjusting the Crossover Effect in Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial. MRC HTMR workshop, Feb 2012, available here 32
Treatment changes in cancer clinical trials: design and analysis
Treatment changes in cancer clinical trials: design and analysis Ian White Statistical methods and designs in clinical oncology Paris, 9 th November 2017 Plan 1. Treatment changes
More informationAdjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial
Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial Xin Huang 1 and Qiang (Casey) Xu 2 1 Pfizer Oncology
More informationAssessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study
Article Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study Statistical Methods in Medical Research 2018, Vol. 27(3) 765 784! The Author(s) 2016 Reprints
More informationThe Logic of Causal Inference. Uwe Siebert, MD, MPH, MSc, ScD
The Logic of Causal Inference Uwe Siebert, MD, MPH, MSc, ScD (1) Dept. of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics
More informationNICE DSU TECHNICAL SUPPORT DOCUMENT 16: ADJUSTING SURVIVAL TIME ESTIMATES IN THE PRESENCE OF TREATMENT SWITCHING
NICE DSU TECHNICAL SUPPORT DOCUMENT 16: ADJUSTING SURVIVAL TIME ESTIMATES IN THE PRESENCE OF TREATMENT SWITCHING REPORT BY THE DECISION SUPPORT UNIT July 2014 Nicholas R Latimer 1 Keith R Abrams 2 1 School
More informationEverolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT
for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT Thank you very much for the opportunity to submit additional analysis in relation to the above technology appraisal
More informationMethods for adjusting survival estimates in the presence of treatment crossover a simulation study
Methods for adjusting survival estimates in the presence of treatment crossover a simulation study Nicholas Latimer, University of Sheffield Collaborators: Paul Lambert, Keith Abrams, Michael Crowther
More informationRegulatory Challenges in Reviewing Oncology Product Applications
Regulatory Challenges in Reviewing Oncology Product Applications Kun He & Rajeshwari Sridhara Division of Biometrics V Office of Biostatistics Center for Drug Evaluation and Research U.S. Food and Drug
More informationStatistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials
Statistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials Dominik Heinzmann, PhD Global Development Team Leader HER2 Associate Director
More informationBiomarkers in oncology drug development
Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: andrew@stonebiostatistics.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available
More informationThe (mis)use of treatment switching adjustment methods in health technology assessment busting some myths!
The (mis)use of treatment switching adjustment methods in health technology assessment busting some myths! ISPOR Barcelona, 2018 Dr Nicholas Latimer (n.latimer@sheffield.ac.uk) Reader in Health Economics,
More informationAccounting for treatment switching/discontinuation in comparative effectiveness studies
Global Medical Affairs RWE and Digital Accounting for treatment switching/discontinuation in comparative effectiveness studies Melvin Skip Olson, PhD Global Head, Real World Data Strategy and Innovation
More informationInverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials.
Paper SP02 Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials. José Luis Jiménez-Moro (PharmaMar, Madrid, Spain) Javier Gómez (PharmaMar, Madrid, Spain) ABSTRACT
More informationAdjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy
Cancer Medicine ORIGINAL RESEARCH Open Access Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy Nicholas R. Latimer
More informationEstimands in oncology
Estimands in oncology Steven Teerenstra 1,2 1 Radboud university Nijmegen medical center, NL 2 Statistical assessor at Medicines Evaluation Board (MEB), NL Disclaimer 2 Views expressed my own, based on
More informationDealing with Treatment Switches in Cost effectiveness Analysis: Martin Pitt Martin Hoyle Peninsula Technology Assessment Group Exeter
Dealing with Treatment Switches in Cost effectiveness Analysis: The NICE Experience Martin Pitt Martin Hoyle Peninsula Technology Assessment Group Exeter Presentation Martin Pitt : The Nice Context and
More informationCost-effectiveness of osimertinib (Tagrisso )
Cost-effectiveness of osimertinib (Tagrisso ) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung
More informationBeyond the intention-to treat effect: Per-protocol effects in randomized trials
Beyond the intention-to treat effect: Per-protocol effects in randomized trials Miguel Hernán DEPARTMENTS OF EPIDEMIOLOGY AND BIOSTATISTICS Intention-to-treat analysis (estimator) estimates intention-to-treat
More informationCancer Immunotherapy from the Health Technology Assessment (HTA) and Payer Perspectives
BBS PSI Scientific Meeting: Empower the immune system to fight cancer Cancer Immunotherapy from the Health Technology Assessment (HTA) and Payer Perspectives Fred Sorenson, Xcenda Disclaimer and Acknowledgements
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationCHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials
CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationAssessing the impact of unmeasured confounding: confounding functions for causal inference
Assessing the impact of unmeasured confounding: confounding functions for causal inference Jessica Kasza jessica.kasza@monash.edu Department of Epidemiology and Preventive Medicine, Monash University Victorian
More informationMethods to control for confounding - Introduction & Overview - Nicolle M Gatto 18 February 2015
Methods to control for confounding - Introduction & Overview - Nicolle M Gatto 18 February 2015 Learning Objectives At the end of this confounding control overview, you will be able to: Understand how
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationPossible causes of difference among regions How to look at the results from MRCT Non-compliance with GCP and/or protocol Apparent Differences (Play of
Outline ICH E17 General Principles for Planning and Design of Multi-Regional Clinical Trials Future MRCTs Based on E17 Guideline Background and Key Principles in E17 Some case studies of Gastric Cancer
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationA (Constructive/Provocative) Critique of the ICH E9 Addendum
A (Constructive/Provocative) Critique of the ICH E9 Addendum Daniel Scharfstein Johns Hopkins University dscharf@jhu.edu April 18, 2018 1 / 28 Disclosures Regularly consult with pharmaceutical and device
More informationEstimands, Missing Data and Sensitivity Analysis: some overview remarks. Roderick Little
Estimands, Missing Data and Sensitivity Analysis: some overview remarks Roderick Little NRC Panel s Charge To prepare a report with recommendations that would be useful for USFDA's development of guidance
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 CPMP/EWP/1776/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO
More informationDabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Dabrafenib for treating unresectable or metastatic BRAF V600 Issued: October 2014 guidance.nice.org.uk/ta321 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE
More informationComparison And Application Of Methods To Address Confounding By Indication In Non- Randomized Clinical Studies
University of Massachusetts Amherst ScholarWorks@UMass Amherst Masters Theses 1911 - February 2014 Dissertations and Theses 2013 Comparison And Application Of Methods To Address Confounding By Indication
More informationSubgroup Mixable Inference for Targeted Therapies
Subgroup Mixable Inference for Targeted Therapies Jason C. Hsu The Ohio State University Duke Industry Statistics Symposium September 2017 In collaboration with Hong Tian, Haiyan Xu, Hui-Min Lin, Ying
More informationEstimating Direct Effects of New HIV Prevention Methods. Focus: the MIRA Trial
Estimating Direct Effects of New HIV Prevention Methods. Focus: the MIRA Trial Michael Rosenblum UCSF: Helen Cheng, Nancy Padian, Steve Shiboski, Ariane van der Straten Berkeley: Nicholas P. Jewell, Mark
More informationNICE decisions on health care provisions in England
NICE decisions on health care provisions in England Matt Stevenson, Professor of Health Technology Assessment (HTA), ScHARR, University of Sheffield, UK A quick introduction I am Technical Director of
More informationEvaluating health management programmes over time: application of propensity score-based weighting to longitudinal datajep_
Journal of Evaluation in Clinical Practice ISSN 1356-1294 Evaluating health management programmes over time: application of propensity score-based weighting to longitudinal datajep_1361 180..185 Ariel
More informationRecent developments for combining evidence within evidence streams: bias-adjusted meta-analysis
EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard
More informationTechnology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy Technology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520 NICE 2018. All rights
More informationAccelerating Innovation in Statistical Design
Implementing a National Cancer Clinical Trials System for the 21 st Century, Workshop #2 Session #5: Accelerating Innovation Through Effective Partnerships Accelerating Innovation in Statistical Design
More informationEverolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression MTA
Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression MTA 1 st Appraisal Committee meeting Cost Effectiveness Committee
More informationRecursive Partitioning Method on Survival Outcomes for Personalized Medicine
Recursive Partitioning Method on Survival Outcomes for Personalized Medicine Wei Xu, Ph.D Dalla Lana School of Public Health, University of Toronto Princess Margaret Cancer Centre 2nd International Conference
More informationResponse to NICE ACD on Sunitinib for the treatment of GIST February This is a joint submission by Sarcoma UK, GIST Support UK
Response to NICE ACD on Sunitinib for the treatment of GIST February 2009 This is a joint submission by Sarcoma UK, GIST Support UK and the Rarer Cancers Forum. We address the four general questions on
More informationErlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer
ERRATUM Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer This report was commissioned by the NIHR HTA Programme as project number 11/08 Completed 6 th January
More informationPopulation-adjusted treatment comparisons Overview and recommendations from the NICE Decision Support Unit
Population-adjusted treatment comparisons Overview and recommendations from the NICE Decision Support Unit David M Phillippo, University of Bristol 3 Available from www.nicedsu.org.uk Outline Background
More informationTechnology appraisal guidance Published: 22 October 2014 nice.org.uk/guidance/ta321
Dabrafenib afenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma Technology appraisal guidance Published: 22 October 2014 nice.org.uk/guidance/ta321 NICE 2018. All rights
More informationBackground Comparative effectiveness of nivolumab
NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued
More informationComparisons of Dynamic Treatment Regimes using Observational Data
Comparisons of Dynamic Treatment Regimes using Observational Data Bryan Blette University of North Carolina at Chapel Hill 4/19/18 Blette (UNC) BIOS 740 Final Presentation 4/19/18 1 / 15 Overview 1 Motivation
More informationStrategies for handling missing data in randomised trials
Strategies for handling missing data in randomised trials NIHR statistical meeting London, 13th February 2012 Ian White MRC Biostatistics Unit, Cambridge, UK Plan 1. Why do missing data matter? 2. Popular
More informationDesigning a Bayesian randomised controlled trial in osteosarcoma. How to incorporate historical data?
Designing a Bayesian randomised controlled trial in osteosarcoma: How to incorporate historical data? C. Brard, L.V Hampson, M-C Le Deley, G. Le Teuff SCT - Montreal, May 18th 2016 Brard et al. Designing
More informationStatistical Challenges for Novel Technologies. Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute
Statistical Challenges for Novel Technologies Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute ISCTM 2016 Autumn Conference, Philadelphia, PA 27 September
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationCausal Effects based on Randomized Clinical and Intervention Trials
Causal Effects based on Randomized Clinical and Intervention Trials Alan Hubbard and Nicholas P. Jewell Division of Biostatistics School of Public Health University of California, Berkeley Workshop on
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations Summary Date prepared: May 2012 Imatinib was the first
More informationSurvival Analysis in Clinical Trials: The Need to Implement Improved Methodology
Survival Analysis in Clinical Trials: The Need to Implement Improved Methodology Lucinda (Cindy) Billingham Professor of Biostatistics Director, MRC Midland Hub for Trials Methodology Research Lead Biostatistician,
More informationEstimands for time to event endpoints in oncology and beyond
Estimands for time to event endpoints in oncology and beyond Kaspar Rufibach, Hans Ulrich Burger Methods, Collaboration & Outreach Group (MCO) Department of Biostatistics, Roche Basel Context and problem
More informationEvaluating Social Programs Course: Evaluation Glossary (Sources: 3ie and The World Bank)
Evaluating Social Programs Course: Evaluation Glossary (Sources: 3ie and The World Bank) Attribution The extent to which the observed change in outcome is the result of the intervention, having allowed
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationTrial designs fully integrating biomarker information for the evaluation of treatment-effect mechanisms in stratified medicine
Trial designs fully integrating biomarker information for the evaluation of treatment-effect mechanisms in stratified medicine Dr Richard Emsley Centre for Biostatistics, Institute of Population Health,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationA NEW TRIAL DESIGN FULLY INTEGRATING BIOMARKER INFORMATION FOR THE EVALUATION OF TREATMENT-EFFECT MECHANISMS IN PERSONALISED MEDICINE
A NEW TRIAL DESIGN FULLY INTEGRATING BIOMARKER INFORMATION FOR THE EVALUATION OF TREATMENT-EFFECT MECHANISMS IN PERSONALISED MEDICINE Dr Richard Emsley Centre for Biostatistics, Institute of Population
More informationGeneralizing the right question, which is?
Generalizing RCT results to broader populations IOM Workshop Washington, DC, April 25, 2013 Generalizing the right question, which is? Miguel A. Hernán Harvard School of Public Health Observational studies
More informationVersion No. 7 Date: July Please send comments or suggestions on this glossary to
Impact Evaluation Glossary Version No. 7 Date: July 2012 Please send comments or suggestions on this glossary to 3ie@3ieimpact.org. Recommended citation: 3ie (2012) 3ie impact evaluation glossary. International
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationEstimands in klinischen Studien: was ist das und geht mich das was an?
Estimands in klinischen Studien: was ist das und geht mich das was an? CTU Lecture 03.04.2018 Sven Trelle Mention > ICH E9(R1) Statistical Principles for Clinical Trials "Addendum to focus on statistical
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More information16:35 17:20 Alexander Luedtke (Fred Hutchinson Cancer Research Center)
Conference on Causal Inference in Longitudinal Studies September 21-23, 2017 Columbia University Thursday, September 21, 2017: tutorial 14:15 15:00 Miguel Hernan (Harvard University) 15:00 15:45 Miguel
More informationPartitioned survival analysis for decision modelling in health care: a critical review
Partitioned survival analysis for decision modelling in health care: a critical review Marta Soares ISPOR, Glasgow 2017 Acknowledgements: Beth Woods, Eleftherios Sideris, Stephen Palmer (University of
More informationin Longitudinal Studies
Balancing Treatment Comparisons in Longitudinal Studies Sue M. Marcus, PhD, is with the Department of Psychiatry, Mount Sinai School of Medicine, New York. Juned Siddique, DrPH, is with the Department
More informationTechnology appraisal guidance Published: 25 February 2015 nice.org.uk/guidance/ta333
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment Technology appraisal guidance Published: 25 February 2015 nice.org.uk/guidance/ta333 NICE 2018. All rights
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Adjuvant imatinib after complete resection of primary gastrointestinal stromal tumour (GIST) in patients at high risk of relapse May 2012 Summary NICE guidance
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationBLISTER STATISTICAL ANALYSIS PLAN Version 1.0
The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Study EudraCT number: 2007-006658-24 ISRCTN: 13704604 BLISTER STATISTICAL ANALYSIS PLAN Version 1.0 Version Date Comments 0.1 13/01/2011 First
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationInfluence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer
Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer Jason D. Wright, MD, Yongemei Huang, MD/PhD, William M. Burke, MD, et al. Journal Club March 16, 2016 Blaine Campbell-PGY2 Objective
More informationBayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer
Original Manuscript Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer Medical Decision Making 1 15 Ó The Author(s) 2018
More informationSensitivity Analysis in Observational Research: Introducing the E-value
Sensitivity Analysis in Observational Research: Introducing the E-value Tyler J. VanderWeele Harvard T.H. Chan School of Public Health Departments of Epidemiology and Biostatistics 1 Plan of Presentation
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationTechnology appraisal guidance Published: 27 July 2016 nice.org.uk/guidance/ta399
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts Technology appraisal guidance Published: 27 July 2016 nice.org.uk/guidance/ta399 NICE 2018. All rights reserved. Subject
More informationReal World Evidence in the Treatment of Ovarian Cancer. Elizabeth Eisenhauer MD FRCPC Queen s University
Real World Evidence in the Treatment of Ovarian Cancer Elizabeth Eisenhauer MD FRCPC Queen s University Outline What is real world evidence (RWE) and how can it shape policy and practice? In ovarian cancer,
More informationLecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method
Biost 590: Statistical Consulting Statistical Classification of Scientific Studies; Approach to Consulting Lecture Outline Statistical Classification of Scientific Studies Statistical Tasks Approach to
More informationEstimands: PSI/EFSPI Special Interest group. Alan Phillips
Estimands: PSI/EFSPI Special Interest group Alan Phillips 1 Agenda PSI/EFSPI Special Interest Group Discussion Framework What is the real problem we are trying to solve? Case study Key messages Definition
More informationBEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS
BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS Nan Shao, Ph.D. Director, Biostatistics Premier Research Group, Limited and Mark Jaros, Ph.D. Senior
More informationNICE DSU TECHNICAL SUPPORT DOCUMENT 19: PARTITIONED SURVIVAL ANALYSIS FOR DECISION MODELLING IN REPORT BY THE DECISION SUPPORT UNIT
NICE DSU TECHNICAL SUPPORT DOCUMENT 19: PARTITIONED SURVIVAL ANALYSIS FOR DECISION MODELLING IN HEALTH CARE: A CRITICAL REVIEW REPORT BY THE DECISION SUPPORT UNIT 2 June 2017 Beth Woods 1, Eleftherios
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationInstrumental Variables Estimation: An Introduction
Instrumental Variables Estimation: An Introduction Susan L. Ettner, Ph.D. Professor Division of General Internal Medicine and Health Services Research, UCLA The Problem The Problem Suppose you wish to
More informationCAUSAL INFERENCE IN HIV/AIDS RESEARCH: GENERALIZABILITY AND APPLICATIONS
CAUSAL INFERENCE IN HIV/AIDS RESEARCH: GENERALIZABILITY AND APPLICATIONS Ashley L. Buchanan A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment
More informationTechnology appraisal guidance Published: 21 March 2018 nice.org.uk/guidance/ta512
Tivozanib for treating advanced renal cell carcinoma Technology appraisal guidance Published: March 2018 nice.org.uk/guidance/ta512 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationDeclaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018
Register-based research on safety and effectiveness opportunities and challenges Morten Andersen Department of Drug Design And Pharmacology Declaration of interests Participate(d) in research projects
More informationConfounding by indication developments in matching, and instrumental variable methods. Richard Grieve London School of Hygiene and Tropical Medicine
Confounding by indication developments in matching, and instrumental variable methods Richard Grieve London School of Hygiene and Tropical Medicine 1 Outline 1. Causal inference and confounding 2. Genetic
More informationDiscussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK
Discussion Meeting for MCP-Mod Qualification Opinion Request Novartis 10 July 2013 EMA, London, UK Attendees Face to face: Dr. Frank Bretz Global Statistical Methodology Head, Novartis Dr. Björn Bornkamp
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationRise of the Machines
Rise of the Machines Statistical machine learning for observational studies: confounding adjustment and subgroup identification Armand Chouzy, ETH (summer intern) Jason Wang, Celgene PSI conference 2018
More informationHow to improve the reliability of Single Arm Trials
Workshop on Single Arm Trials in Oncology Products EMA, London, June 30, 2016 How to improve the reliability of Single Arm Trials Paolo Bruzzi Clinical Epidemiology Unit IRCCS San Martino-IST - National
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following
More informationDRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials
DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop
More informationBeyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies
September 27, 2018 Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies A Case Study of Screening Colonoscopy Our Team Xabier Garcia
More informationComparing treatments evaluated in studies forming disconnected networks of evidence: A review of methods
Comparing treatments evaluated in studies forming disconnected networks of evidence: A review of methods John W Stevens Reader in Decision Science University of Sheffield EFPSI European Statistical Meeting
More informationStatistics for Clinical Trials: Basics of Phase III Trial Design
Statistics for Clinical Trials: Basics of Phase III Trial Design Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, Colorado USA NCIC Clinical Trials Group
More information